Verified peer comparison

JNJ vs MRK

Johnson & Johnson compared with Merck & Co., Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

JNJ

Johnson & Johnson

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

MRK

Merck & Co., Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

JNJ: Pharmaceuticals

MRK: Pharmaceuticals

Upside lens

JNJ: Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products. Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth. Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.

MRK: Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses. Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products. A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.

Risk lens

JNJ: Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts. Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines. Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.

MRK: Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks. Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches. Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.